Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront

Biogen, a Cambridge , MA biopharma, in-licensed ex-China rights to a biosimilar aimed at rheumatoid arthritis from Guangzhou 's Bio-Thera. The candidate, BAT1806, is a proposed biosimilar to Roche's Actemra® (tocilizumab). It is an anti-interleukin-6 (IL-6) receptor mAb that is currently in Phase III trials. Biogen will make a $30 million upfront payment once BAT1806 reports satisfactory Phase III results, plus unspecified milestones and royalties. More details.... Stock Symbols: (NSDQ: BIIB) (SHA: 688177) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.